Celltrion USA presents two-year data on ZYMFENTRA™ (infliximab-dyyb) for IBD at DDW 2024.
Celltrion USA will present two-year data from the extended LIBERTY studies on ZYMFENTRA™ (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, at the Digestive Disease Week (DDW) 2024 Annual Meeting in Washington, D.C. The data highlights the long-term treatment goals and underscores Celltrion's commitment to improving patient outcomes and advancing scientific understanding in the field of inflammatory bowel disease (IBD).
May 17, 2024
6 Articles